Long-term survival outcomes after lobe-specific nodal dissection in patients with early non-small-cell lung cancer

被引:3
|
作者
Kamigaichi, Atsushi [1 ]
Aokage, Keiju [1 ,3 ]
Ikeno, Takashi [2 ]
Wakabayashi, Masashi [2 ]
Miyoshi, Tomohiro [1 ]
Tane, Kenta [1 ]
Samejima, Joji [1 ]
Tsuboi, Masahiro [1 ]
机构
[1] Natl Canc Ctr Hosp East, Div Thorac Surg, Kashiwa, Japan
[2] Natl Canc Ctr Hosp East, Clin Res Support Off, Kashiwa, Japan
[3] Natl Canc Ctr Hosp East, Div Thorac Surg, 6-5-1 Kashiwanoha, Kashiwa, Chiba 2778577, Japan
关键词
Non-small-cell lung cancer; Lobe-specific nodal dissection; Systematic nodal dissection; Long-term outcome; CLINICAL STAGE-I; MEDIASTINAL LYMPHADENECTOMY; RANDOMIZED-TRIAL; SURGERY; CLASSIFICATION; RESECTION; NSCLC;
D O I
10.1093/ejcts/ezad016
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVES:We investigated the long-term outcomes of lobe-specific nodal dissection (LSD) and systematic nodal dissection (SND) in patients with non-small-cell lung cancer (NSCLC).METHODS: Patients with c-stage I and II NSCLC who underwent lobectomy with mediastinal nodal dissection were retrospectively analysed. After propensity score matching, we assessed the overall survival (OS), recurrence-free survival (RFS) and cumulative incidence of death (CID) from primary lung cancer and other diseases.RESULTS:The median follow-up period was 8.4 years. Among 438 propensity score-matched pairs, OS and RFS were similar between the LSD and SND groups [hazard ratio (HR), 0.979; 95% confidence interval (CI), 0.799-1.199; and HR, 0.912; 95% CI, 0.762-1.092, respectively], but the LSD group showed a better prognosis after 5 years postoperatively. CID from primary lung cancer was similar between the 2 groups (HR, 1.239; 95% CI, 0.940-1.633). However, the CID from other diseases was lower in the LSD group than in the SND group (HR, 0.702; 95% CI, 0.525-0.938). According to c-stage, the LSD group tended towards worse OS and RFS, with higher CID from primary lung cancer than the SND group, in patients with c-stage II.CONCLUSIONS: LSD provides acceptable long-term survival for patients with early-stage NSCLC. However, LSD may not be suitable for patients with c-stage II NSCLC due to the higher mortality risk from primary lung cancer.
引用
收藏
页数:10
相关论文
共 50 条
  • [21] Preoperative Risk Factors of Potential Failure for Lobe-Specific Nodal Dissection in Clinical Early Stage (I-IIA) Non-Small Cell Lung Cancer
    Chong, Y.
    Yun, J. K.
    Jeong, Y. H.
    Lee, G. D.
    Choi, S.
    Kim, H. R.
    Kim, Y.
    Park, S.
    Kim, D. K.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S886 - S887
  • [22] Long-Term Survival of Patients with Metastatic Non-Small-Cell Lung Cancer over Five Decades
    Bar, Jair
    Urban, Damien
    Amit, Uri
    Appel, Sarit
    Onn, Amir
    Margalit, Ofer
    Beller, Tamar
    Kuznetsov, Teodor
    Lawrence, Yaacov
    JOURNAL OF ONCOLOGY, 2021, 2021
  • [23] Mediastinal Nodal Involvement in Patients with Clinical Stage I Non-Small-Cell Lung Cancer Possibility of Rational Lymph Node Dissection
    Haruki, Tomohiro
    Aokage, Keiju
    Miyoshi, Tomohiro
    Hishida, Tomoyuki
    Ishii, Genichiro
    Yoshida, Junji
    Tsuboi, Masahiro
    Nakamura, Hiroshige
    Nagai, Kanji
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (06) : 930 - 936
  • [24] Impact of L4 lymph node dissection on long-term survival in left-side operable non-small-cell lung cancer: a propensity score matching study
    Yang, Mu-Zi
    Hou, Xue
    Li, Ji-Bin
    Cai, Jing-Sheng
    Yang, Jie
    Li, Shuo
    Long, Hao
    Fu, Jian-Hua
    Zhang, Lan-Jun
    Lin, Peng
    Rong, Tie-Hua
    Yang, Hao-Xian
    EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2020, 57 (06) : 1181 - 1188
  • [25] Lobe-Specific Lymph Node Dissection for Clinical Early-Stage (cIA) Peripheral Non-Small Cell Lung Cancer Patients: Feasible and How?
    Deng, H.
    Zhou, Q.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S615 - S615
  • [26] Is Lobe-Specific Lymph Node Dissection in Clinical N0-1 Non-Small Cell Lung Cancer Adequate for Pathological Nodal Staging
    Tantraworasin, A.
    Siwachat, S.
    Lertprasertsuke, N.
    Kongkarnka, S.
    Euathrongchit, J.
    Wannasopha, Y.
    Tanatip, N.
    Taioli, E.
    Saeteng, S.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1753 - S1753
  • [27] Long-term survival of patients treated with photodynamic therapy for carcinoma in situ and early non-small-cell lung carcinoma
    Corti, Luigi
    Toniolo, Lamberto
    Boso, Caterina
    Colaut, Flavio
    Fiore, Davide
    Muzzio, Pier-Carlo
    Koukourakis, Michael I.
    Mazzarotto, Renzo
    Pignataro, Michele
    Loreggian, Lucio
    Sotti, Guido
    LASERS IN SURGERY AND MEDICINE, 2007, 39 (05) : 394 - 402
  • [28] A randomized Phase III trial of lobe-specific vs. systematic nodal dissection for clinical Stage I-II non-small cell lung cancer (JCOG1413)
    Hishida, Tomoyuki
    Saji, Hisashi
    Watanabe, Shun-ichi
    Asamura, Hisao
    Aokage, Keiju
    Mizutani, Tomonori
    Wakabayashi, Masashi
    Shibata, Taro
    Okada, Morihito
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2018, 48 (02) : 190 - 194
  • [29] Is systematic lymph node dissection mandatory or is sampling adequate in patients with stage I non-small-cell lung cancer?
    Mitsos, Sofoklis
    Panagiotopoulos, Nikolaos
    Patrini, Davide
    George, Robert S.
    INTERACTIVE CARDIOVASCULAR AND THORACIC SURGERY, 2019, 28 (04) : 550 - 554
  • [30] Nodal recurrences after stereotactic body radiotherapy for early stage non-small-cell lung cancer
    Tibdewal, Anil
    Pathak, Rima S.
    Agarwal, Jai Prakash
    Hoskote, Sumedh S.
    Mummudi, Naveen
    Iyer, Veena
    Nair, Akshay G.
    CURRENT PROBLEMS IN CANCER, 2021, 45 (02)